Raymond James Financial
FHTX icon

Raymond James Financial’s Foghorn Therapeutics FHTX Stock Holding History

Raymond James Financial’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2M Sell
2,489,978
-112,404
-4% -$499K ﹤0.01% 1990
2026
Q1 		$12.4M Buy
2,602,382
+96,561
+4% +$530K ﹤0.01% 1834
2025
Q4 		$13.5M Buy
2,505,821
+43,333
+2% +$196K ﹤0.01% 1731
2025
Q3 		$12M Buy
2,462,488
+95,196
+4% +$505K ﹤0.01% 1774
2025
Q2 		$11.1M Buy
2,367,292
+148,940
+7% +$622K ﹤0.01% 1783
2025
Q1 		$8.1M Buy
2,218,352
+188,969
+9% +$861K ﹤0.01% 1984
2024
Q4 		$9.58M Buy
+2,029,383
New +$14.8M ﹤0.01% 1883

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial's FHTX Position: Q2 2026 in Review

Raymond James Financial reduced its Foghorn Therapeutics (FHTX) stake by 4.3% in Q2 2026, selling an estimated $499K and leaving 2,489,978 shares worth $12.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1990.

Raymond James Financial first reported a position in FHTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $13.5M in Q4 2025. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Raymond James Financial held 2,489,978 shares of Foghorn Therapeutics worth $12.2M as of Q2 2026.
  • Raymond James Financial sold 112,404 Foghorn Therapeutics shares in Q2 2026, an estimated $499K.
  • Foghorn Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #1990 holding.
  • Raymond James Financial first reported a position in Foghorn Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Raymond James Financial's Foghorn Therapeutics position peaked at $13.5M in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.